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Zebrafish reproduce in large quantities, grow rapidly, and are transparent early in development. For these reasons, zebrafish have been used
extensively to model vertebrate development and disease. Like mammals, zebrafish express dystrophin and many of its associated proteins early in
development and these proteins have been shown to be vital for zebrafish muscle stability. In dystrophin-null zebrafish, muscle degeneration
becomes apparent as early as 3 days post-fertilization (dpf) making the zebrafish an excellent organism for large-scale screens to identify other
genes involved in the disease process or drugs capable of correcting the disease phenotype. Being transparent, developing zebrafish are also an
ideal experimental model for monitoring the fate of labeled transplanted cells. Although zebrafish dystrophy models are not meant to replace
existing mammalian models of disease, experiments requiring large numbers of animals may be best performed in zebrafish. Results garnered from
using this model could lead to a better understanding of the pathogenesis of the muscular dystrophies and the development of future therapies.
© 2006 Elsevier B.V. All rights reserved.Keywords: Zebrafish; Muscular dystrophy; Dystrophin; Animal models; Therapy1. Introduction
Muscular dystrophy is a progressive muscle degenerative
disease in which the muscle forms normally, but degenerates
faster than it can be repaired. Mutations in the dystrophin gene
have been shown to cause Duchenne Muscular Dystrophy and
the less severe Becker Muscular Dystrophy, the most common
forms of the disease [1]. Interestingly, dystrophin was one of the
first human disease genes discovered through positional cloning
[2–4]. The human dystrophin gene encodes a large protein that
localizes to the intracellular portion of the muscle sarcolemmal
membrane [5–7]. Further analysis showed that dystrophin is
part of a large membrane-bound complex called the dystrophin
associated protein complex (DAPC) [8–10]. Mutations in many
of the DAPC proteins have since been shown to cause different☆ Due to space limitations, many references were not included. We sincerely
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doi:10.1016/j.bbadis.2006.07.003forms of muscular dystrophy, suggesting that this complex is
important for maintaining muscle integrity [11–15]. Linkage
analysis has been used in human patient samples to show that
mutations in non-DAPC genes can also cause muscular
dystrophy (reviewed in [16]).
DuchenneMuscular Dystrophy (DMD) is an X-linked genetic
disorder presenting in approximately 1 in 3500 live male births.
DMD is caused bymutations in the dystrophin gene that typically
result in the near complete loss of the protein at the sarcolemmal
membrane. Loss of dystrophin expression destabilizes the entire
DAPC, likely weakening the sarcolemma to allow local
perforation and calcium influxes, and potentially disrupting
DAPC-associated signaling pathways (reviewed in [17]). DMD
patients first show symptoms between 1 and 5 years of age,
beginning with weakening of the proximal muscles and quickly
extending to distal muscles, particularly the legs. Eventually, the
disease affects almost all voluntary muscles and patients may also
present with cardiac involvement to varying degrees.
The limb-girdle muscular dystrophies show a similar
pattern of affected muscle, but are inherited in either
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(LGMD 2A–K) inheritance modes. In addition, LGMDs can
vary in age of onset, rate of progression, and presence of
accompanying mental retardation. Several other muscular
dystrophies have been identified, including congenital MDs
with frequent central nervous system involvement and far less
progressive weakening, as well as distal myopathies which
show more limited muscle group participation.
Mutations in over 25 genes have been shown to be the
underlying basis of many of the muscular dystrophies (reviewed
in [16]). In addition, there remain at least 5 forms of muscular
dystrophy for which the causative mutant gene has yet to be
identified suggesting that additional dystrophy genes remain
unknown. The known genes encode proteins which position to
four main cellular compartments in muscle cells, including the
nucleus, the Golgi apparatus, the sarcomere, and the sarcolem-
mal membrane. The fact that mutations in seemingly unrelated
proteins positioned in various cellular compartments can all
cause clinically similar forms of disease suggests that additional
adaptor molecules remain to be identified. Given the likely
importance of these adaptor molecules, it is also possible that
mutations in these genes could be lethal in mammals. For this
and other reasons, many laboratories have resorted to using
animal models like zebrafish in which all developmental stages
can be easily assayed (reviewed in [18]).
2. Animal models for muscular dystrophy
2.1. Current animal models
There are many well established animal models for muscular
dystrophy (reviewed in [19]). Animal models are frequently
used to model human disease because their environment and
reproduction can be controlled, their generation times are
typically short, and they can be easily used to evaluate the
effectiveness of potential therapies. Between different animal
species, these advantages can vary widely such that specific
animals are often selected to address specific questions.
While there are many vertebrate models of muscular
dystrophy, the most commonly used is the mdx mouse [20].
This mouse carries a nonsense mutation in exon 23 of the
dystrophin gene and is predominantly dystrophin-null [20].
However, exon 23 is prone to skipping and therefore the number
of revertant muscle fibers in this model can be a concern.
Revertant fibers can successfully circumvent the mutation and
express a modified form of dystrophin. While the mdx mutant
mouse was isolated naturally, other mouse models were isolated
as part of a genetic screen [21,22]. The mdx5cv mouse has a
point mutation in exon 10 affecting splicing and shows fewer
revertant fibers than the mdx mouse [22]. The resulting
phenotype in the mdx5cv mouse is more severe than the mdx
mouse, potentially making the mdx5cv mutant a better model for
evaluating the effectiveness of different therapies.
While the mouse is the most commonly used dystrophy
model, dog models of muscular dystrophy are thought to have
a phenotype more similar to that of humans [23]. For
example, the muscle in the mdx dystrophin-null mouseundergoes less degeneration and regeneration than the muscle
of dystrophin-null humans or dogs. While there are obvious
limitations for maintaining large animal models, dogs can
serve as excellent models for evaluating specific therapies
(reviewed in [24,25]).
Currently, many potential therapies are evaluated by
introducing fluorescently tagged proteins or cells into a diseased
animal and then following their fate using fluorescence to
determine if the introduced proteins or cells localize to muscle
and participate in the repair process. While systems are available
for monitoring transplanted cells in living mouse models, these
systems can be relatively expensive and/or difficult to get
resolution high enough to identify single cells in the host animal.
As such, expression of the introduced protein is often evaluated
by euthanizing the animal several months after the therapeutic
intervention and sectioning the muscle to determine whether any
of the muscle fibers are marked as arising from the donor cells.
Since the assay is terminal, the effectiveness of the therapy is
evaluated at a single time-point which can make it difficult to
deduce exactly how the transplanted cells produced the resultant
phenotype.
2.2. Advantages and disadvantages using zebrafish models of
disease
Some of the obvious advantages for using zebrafish as a
disease model include its small size (about 1.5 in. full grown),
rapid ex-utero development, optical clarity of the embryos and
early larvae, high reproductive capacity (a single female may
produce up to 300 eggs once every 5–7 days), and short
generation time (3 months). In addition, there is strong
similarity between the zebrafish and human genomes with
significant degrees of synteny between conserved genes [26]
(see also http://www.sanger.ac.uk/Projects/D_rerio/ and http://
genome.ucsc.edu/cgi-bin/hgGateway). In addition, orthologous
genes in both organisms have been shown to regulate similar
developmental processes such as T cell development (reviewed
in [27]). All of these traits make the zebrafish an excellent
model for examining vertebrate development, and for perform-
ing genetic screens requiring large numbers of animals
(reviewed in [28]). In addition, zebrafish are ideally suited for
performing real-time analysis to assay the fate of transplanted
cells. Cells labeled with GFP can be transplanted into
transparent early zebrafish embryos and the fate of the
transplanted cells can be monitored real-time without harm to
the animal (see Section 5.4).
While zebrafish can be an ideal model for vertebrate
development (perspective in [29]), there are some intrinsic
disadvantages to the system. Because zebrafish are evolutionarily
more distant from humans than mammalian dystrophy models,
findings from fish experiments will likely have to be replicated in
mammals before being directly correlated to human therapy.
However, the fact that zebrafish express many of the same
dystrophy associated proteins as humans and that mutations in
these proteins can cause phenotypes similar to those seen in
human patients suggests that findings from fish experiments are
likely to be transferable to mammals (see below).
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been problematic to generate zebrafish with specific mutations,
although procedures for performing homologous recombination
in zebrafish ES cells have recently been reported [30]. In
addition, the zebrafish genome underwent an additional
duplication event after the fish and mammalian lineages
diverged [31,32] such that, in some instances, the zebrafish
can be polyploid for specific genes. Since many zebrafish
mutants have been genetically isolated over the last 20 years
using traditional diploid screens, it is thought that many of the
duplicated genes have either been inactivated or have divided
function between the duplicated genes. Other disadvantages
include a limited number of cross-reacting antibodies and the
modest costs associated with starting a zebrafish facility.
Despite these limitations, the advantages for establishing
zebrafish models of human disease can far outweigh the costs
such that the simultaneous use of both fish and mouse models
would be faster and more economical than relying solely on
mammalian models.
3. Zebrafish muscle development
3.1. Early muscle development
Over the years, zebrafish have been used as an outstanding
developmental model. With regards to muscle, zebrafish have
been utilized to distinguish which progenitor cells are destined
to differentiate into different muscle fiber types since fast and
slow muscle fibers position to different parts of the developing
fish. Fish slow muscle is generally found just underneath the
skin whereas the fast muscle is located more internally [33,34].
In mammals, slow and fast muscle fibers are intermingled. In
both fish and mammals, fast muscle fibers function anaerobi-
cally and are used for short powerful bursts whereas slowmuscle
fibers function aerobically and are used for sustained activity.
During zebrafish development, slow muscle originates from
adaxial cells which migrate from the presomitic mesoderm
through the developing myotome (reviewed in [35–37]).
Adaxial cells have been shown to express early myogenic
markers like MyoD [38] and Myf5 [39], and their migration
through the myotome has been shown to be dependant on the
expression of M- and N-cadherin [40]. Adaxial cells were
named due to their initial location near the axial mesodermal
cells that later derive the notochord. The position of the adaxial
cells suggested that hedgehog factors, which are notochord
derived signaling factors, could direct the fate of adaxial cells
(reviewed in [41]). The analysis of the zebrafish mutant sonic-
you showed that mutations in the sonic hedgehog signaling
pathway could adversely effect muscle development [42]. In
slow muscle mutants, the smoothened protein was found to be
critical for hedgehog signaling and the development of slow
muscle [43,44]. Interestingly, the differentiation of certain fast
muscle fibers in zebrafish has also been shown to be indirectly
regulated by the same hedgehog signaling pathways. Henry et
al. recently showed that migrating cells transiting the myotome
to generate the superficial slow muscle induce a wave of fast
fiber differentiation in the cells through which they migrate[45]. Fast muscle differentiation has also been shown to be
driven by Fgf8 expression [46].
3.2. Muscle development in adult zebrafish
While many developmental pathways are well established in
mammals, less is known about adult muscle development and
maintenance. It has been established that satellite cells are the
main muscle precursor cell in adults. Muscle satellite cells are
committed mononuclear muscle precursors that position to the
inside of the basal lamina in adult muscle tissue [47]. When
signaled, they can divide to generate cells capable of
contributing to myofiber repair (reviewed in [48]). Experiments
in mice and chicks have shown that adult muscle satellite cells
are originally derived from the dermomyotome of the develop-
ing embryo [49,50]. Specifically, skeletal muscle satellite cells
in the limb [50] and trunk [51] have been shown to develop
from Pax3 expressing cells. Pax3 is a paralogue of Pax7, an
early marker of muscle satellite cells [52,53]. In adult muscle, it
is possible that satellite cells could also originate from other less
committed cells within muscle [54,55] or blood [56,57]. There
are significant therapeutic ramifications associated with the
positive identification of these cells as they could theoretically
be modified and transplanted into patients for cell therapy to
treat muscular dystrophy.
While it is unknown exactly how muscle regenerates in adult
zebrafish, satellite cells have been identified in other fish
species, including Atlantic salmon [58,59]. Although salmon
are clearly different than zebrafish, the identification of c-met (a
satellite cell marker) positive mononuclear cells within muscle
suggests that muscle development in other fish is likely to be
conserved [58]. Unlike mammals, zebrafish retain their somitic
structure throughout development and each muscle fiber
stretches from one myosepta to the next. This difference
suggests that satellite cells in zebrafish could position anywhere
in the somite and still enable fusion-competent cells access to
existing myofibers. As in mammals, zebrafish blastulae or adult
muscle mononuclear cell cultures can differentiate into
myofibers in culture indicating the presence of muscle precursor
cells ([60], Kunkel, unpublished data). Like mammals, fully
developed zebrafish muscle fibers are multinucleated, although
muscle striation can occur in certain muscle fibers before fusion
in developing zebrafish [61,62].
4. Muscular dystrophy in zebrafish
4.1. Isolation of zebrafish muscle mutants
One of the early zebrafish mutational screens was published
in 1990 and described the isolation of the muscle mutant fub-1
(fibrils unbundled) [63]. Gamma ray irradiation was used as the
mutagen and, in a screen of 225 fish, two different fub-1 alleles
were identified. This mutant showed disorganized muscle fibers
early in development [64], although the causative mutation has
yet to be identified.
In 1996, as part of a large genetic screening effort in
Tuebingen, Germany, almost 3,000 zebrafish mutant families
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the categories included 166 motility mutants which were further
subgrouped into 14 phenotypically distinct groups [66,67].
From this categorization, 4 unique alleles and 5 unresolved
alleles were found to exhibit normal muscle at 2 dpf, but
decreased muscle organization by 5 dpf [67]. Muscle disorga-
nization was assayed using birefringence (Fig. 1A), a technique
used in the initial characterization of muscle [68]. Birefringence
is a phenomenon in which the highly ordered somitic muscle has
the unique property of being able to rotate polarized light. This
can be easily monitored by placing muscle (or a whole fish)
between two polarizing filters and aligning the filters until only
the rotated light is visible. Using this assay, a decrease in the
amount of rotated light could be indicative of the loss of the
sarcomeric structure within muscle whereas dark patches in the
muscle could be indicative of muscle tearing or muscle fiber
disorganization.
4.2. Using zebrafish to understand the pathogenesis of
muscular dystrophy
Since the muscle in one particular Tuebingen subgroup of
fish appeared to develop normally and then degenerate, these
mutants were labeled as potentially dystrophic [67]. It was not
until 2003 that the first of these dystrophic mutants was
characterized [69]. By mapping the mutation and using a
candidate gene approach, Bassett et al. found that the sapje
mutant contained a nonsense mutation in exon 4 of the zebrafish
dystrophin gene [69]. They demonstrated that the muscle in the
sapje fish was degenerating due to the failure of the somiticFig. 1. Sapje mutants show decreased birefringence, inactivity and bending at 7 dpf
shows patchy skeletal muscle birefringence. Birefringence is assayed by placing the
and measuring the light rotated by the muscle. (B) 7 dpf sapjemutants are relatively in
conformation on the bottom of the Petri dish. The location of the swim bladder is inmuscle attachments at the embryonic myotendinous junctions
(reviewed in [70]).
Earlier work showed by immunohistochemistry that zebra-
fish express dystrophin at the sarcolemmal membrane in adult
zebrafish [71,72]. Bolanos-Jimenez et al. used in situ
hybridization to localize dystrophin expression in developing
embryos to the transverse myosepta [73] and mapped the
dystrophin gene to linkage group 1 [74]. Using short interfering
RNA mediated gene targeting, Dodd et al. inhibited dystrophin
expression and showed that the developing embryos had
disorganized sarcomeres and body defects [75]. When mor-
pholinos were used to inhibit dystrophin translation in
developing embryos, the zebrafish were inactive at 5 dpf and
a fraction of them were bent [71]. Western blot and
immunohistochemistry analysis of the dystrophin morphants
confirmed that dystrophin was down-regulated, as were other
members of the dystrophin associated protein complex [71].
This is similar to what happens in mammals with mutations in
dystrophin [76] and suggests that the biochemistry of the
zebrafish dystrophin associated protein complex is similar to
that of humans. In addition, when δ-sarcoglycan (a member of
the muscle DAPC) was down-regulated in early embryos, the
sarcoglycan subcomplex was destabilized, but dystrophin
expression was normal [77]. Again, this is exactly as occurs
in patients with Limb-Girdle Muscle Dystrophy type 2F due to
mutations in δ-sarcoglycan [14] suggesting that the overall
biochemical nature of the complex is conserved.
When the dystrophin morphant was compared to the sapje
mutant, both fish were found to be inactive with somitic lesions
[69], most had a delay in swim bladder inflation (Fig. 1B), and. (A) As reported previously [84], the zebrafish dystrophin-null mutant (sapje)
zebrafish between two polarizing filters rotated 90 degrees relative to each other
active, have an un-inflated their swim bladder, and adopt an energy efficient bent
dicated with an arrow.
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mutant, the dystrophin morphants showed a less severe
birefringence phenotype [69]; however, this may be because the
effectiveness of the morpholino was near its limit at 5 dpf when
the defects in birefringence were most apparent in the sapje
mutant.
Dystroglycan was one of the first members of the dystrophin
associated protein complex thatwas investigated in zebrafish [78].
When dystroglycan was down-regulated using morpholinos to
inhibit translation of the protein, the morphant embryos were
developmentally delayed, had a hooked tail, and showed
compromised muscle integrity [78]. While dystroglycan-null
mice die during development due to defects in the Reichert's
membrane [79], zebrafish develop outside the mother and
therefore dystroglycan-null fish developed and provided novel
insight into dystroglycan's role in vertebratemuscle development.
Morpholino experiments have also been used to down-regulate δ-
sarcoglycan, laminin α2, and caveolin-3 [77,80–82], all genes in
which mutations in the mammalian orthologue have been linked
to muscular dystrophy. In all instances, down-regulation of these
proteins early in development results in fish with decreased
muscle organization [77,80–82].
Interestingly, zebrafish that lack proteins associated with
muscular dystrophy show a phenotype relatively earlier in
development than humans. For example, the sapje mutant
shows muscle degeneration as early as 3 dpf [67] whereas
Duchenne patients normally do not normally show symptoms of
disease until they are 3–4 years old. This might be explained
since utrophin, a dystrophin homologue than can substitute for
dystrophin early in mammalian development [83], is not
expressed in early zebrafish muscle fiber ends like dystrophin
[84]. As such, it is likely that zebrafish lacking functional
dystrophin will show a severe phenotype more similar to mice
lacking both dystrophin and utrophin [85].
As mentioned previously, a number of dystrophic fish were
isolated as part of the first Tuebingen screen [67]. To date, only
one of them has been characterized and this fish was shown to
have a mutation in dystrophin [84]. The characterization of this
family of mutants and mutants isolated from other genetic
screens will be very useful to uncover additional genes involved
in the pathogenesis of muscular dystrophy. In addition to
identifying additional dystrophy associated genes, dystrophic
zebrafish mutants can also be used to evaluate future therapies.
5. Using zebrafish to evaluate therapies for muscular
dystrophy
5.1. Background
While significant inroads are being made to treat muscular
dystrophy, there are currently no curative treatment options for
those afflicted with the disease. At this time, patients diagnosed
with muscular dystrophy are treated with various catabolic
steroids such as prednisone and deflazacort [86]. Although the
mechanism(s) by which these drugs work is not completely
clear, studies have shown that these glucocorticoids might
mitigate symptoms associated with muscle degeneration,stimulate muscle repair, and/or inhibit muscle degeneration
[87–89]. Other treatments currently being tested or considered,
include gentamycin treatment (which encourages read-through
of nonsense mutations) [90], myostatin down-regulation
(encourage muscle development by down-regulating myostatin)
[91,92], and drug therapy using catabolic steroids (like
prednisone) or anabolic steroids (like oxandrolone) [93–95].
As with many genetic disorders, there are two main ways to
potentially treat the muscular dystrophies. First, drug therapy
can be used to either mitigate the symptoms of disease (indirect)
or supply the missing chemical that the cell needs (direct).
Second, protein therapy can be used to supply the missing gene
or protein using either various DNA vectors (gene therapy) or
by transplanting whole cells (cell therapy). All therapies have
the potential to correct the symptoms of disease although each
has its inherent disadvantages. For example, it can be difficult to
identify potential drugs from libraries of millions of different
chemicals. Currently, drugs are often identified based on
positive effects found for one specific cell population, but
these same drugs can often have deleterious effects on other
“non-target” cells. Gene therapy can be associated with both an
adverse immune response to the foreign delivery vectors and
also the inherent problems associated with random genome
integration events (reviewed in [96]). Cell therapy can be used
to circumvent both the immune and integration problems
associated with gene therapy, yet tests in dystrophic mice have
found it difficult to deliver therapeutic levels of protein to the
diseased cells ([97,98], reviewed in [99]).
5.2. Drug screens in zebrafish
As drug discovery using mammals can be very expensive,
mammalian disease models are normally only used to test
limited numbers of compounds, typically those that are first
screened using cell culture. While it is more efficient to test
larger numbers of compounds in cell culture, this is an artificial
environment in which the cells may respond very differently
than in a living organism. These problems can be circumvented
in zebrafish as they are small and reproduce in large enough
numbers such that they can be efficiently used to assay for
therapeutic changes in the context of a living disease model. To
illustrate, the muscle degeneration phenotype in the dystrophin-
null sapje mutant zebrafish is transmitted in a recessive manner
such that 25% of the offspring become dystrophic after 3 dpf.
As such, in a clutch of 300 offspring, 75 would show
phenotype. By crossing many fish, it is possible to quickly
produce large numbers of mutant offspring that can then be
arrayed on plates and exposed to different chemicals in their
water. Chemicals which diffuse into the dystrophic mutant and
mitigate the symptoms of disease would be considered for
potential treatments.
To date, a number of chemical/drug screens have been
published using zebrafish embryos (reviewed in [100]). These
screens have demonstrated the ability to isolate small molecules
capable of altering wildtype embryonic zebrafish development
of several organ systems, including the central nervous system,
cardiovascular system, eye, and ear. The most recent two
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diseases to identify chemical suppressors of disease phenotypes.
Peterson et al. employed the hey2 gene mutant, gridlock (grl),
which presents with aorta malformations similar to human aortic
coarctation [101]. Exposure of mutant embryos to dissolved
chemical compounds in 96-well plates identified a class of
chemicals that upregulates the angiogenic gene VEGF, suppres-
sing the grl phenotype. Stern et al. recently showed the
suppression of a cell-cycle mutant, crash&burn (crb), which
carries a bymb mutation [102]. Roughly 16,000 chemical
compounds were screened in 16 weeks using crb mutants,
allowing for the identification of a novel cell-cycle regulating
drug. These results demonstrate the feasibility of chemical
screens to ameliorate disease phenotypes using zebrafishmodels.
In mammals, mutations that affect splicing, translation, or
transcription have all been shown to cause different forms of
muscular dystrophy. Therefore, different drugs may have
different effects based on the origin of the causative mutation.
Establishing representative zebrafish models that have muscular
dystrophy due to mutations in different genes is therefore just as
important as establishing zebrafish models with different
mutations in the same gene. This is similar to having multiple
mouse models with different mutations in dystrophin (see
discussion regarding mdx versus mdx5CV mouse models).
Established zebrafish disease models would then be ideally
suited for use in chemical screens to select drug candidates
capable of correcting the phenotype.
5.3. Gene therapy approaches for treating muscular dystrophy
Gene therapy holds significant promise for treating people
with genetic disorders like muscular dystrophy. The goal would
be to introduce a corrective gene into muscle to either address
the cause or treat the symptoms of disease. While gene therapy
holds great promise, there are a number of technical issues that
are still being addressed. For instance, current limitations
include the insertion size limit of the delivery vector, the
immune response associated with the delivery vector and/or the
newly expressed wild-type gene, random integration events for
certain vectors that could disrupt the expression of normal
genes, and the vast numbers of skeletal, smooth, and cardiac
muscle cells that would have to be “corrected”.
Gene therapy can either be direct (addressing the cause of
disease) or indirect (addressing the symptoms of disease). While
zebrafish have not yet specifically been used to investigate gene
therapy approaches to treat muscular dystrophy, there are a
number of potential strategies that could be helpful using
zebrafish as disease models. For instance, dystrophin is a large
gene and extensive work has been done in mice to identify a
smaller form of the gene that could fit into viral delivery vectors
[103,104]. This work could be continued in zebrafish mutants or
morphants to either (1) further delimit the functional size of
large genes like dystrophin or (2) to perform domain analysis to
study protein function. Similarly, zebrafish can be used to
discover whether DNA anomalies identified in humans are
disease causative or simply random polymorphisms. In all
cases, these experiments can be performed by injecting specificmorphants or mutants with mRNA constructs (human or
zebrafish) in an attempt to rescue the early fish dystrophic
phenotype. This approach has been used recently to confirm
that a mutation in TRIM32 was causative for Bardet–Biedl
syndrome [105]. In this instance, human TRIM32 mRNAwith a
Bardet–Biedl syndrome causing mutation failed to complement
TRIM32 morphants which showed a disruption in the Kupffer's
vesicle and a delay of intracellular transport. Importantly, a
control human mRNA co-injected in a separate experiment
could rescue the phenotype [105].
In a recent review, Engvall and Wewer described the utility
of modifying the expression of booster genes for treating
muscular dystrophy [106]. These are genes that are not mutated
in patients with muscular dystrophy but whose expression can
address the symptoms of disease. For example, integrin α7β1
and the DAPC are the two major cell adhesion complexes found
in muscle [107]. In patients with Duchenne Muscular
Dystrophy, the DAPC is lost and it has been hypothesized
that upregulating the integrin α7β1 complex could help
stabilize the muscle cell membrane. In testing this hypothesis,
Burkin et al. showed that over-expression of integrin α7 in mdx/
utr deficient mice helps prolong the lifespan and ameliorates
their dystrophy symptoms [107,108]. Due to the ease of making
transgenic zebrafish or of transiently expressing the protein
using mRNA injection, zebrafish are an ideal platform for
testing hypotheses for treating muscular dystrophy via altered
expression of booster genes.
While over-expressing integrin α7, GalNAc transferase,
NOS, Adam12, and calpastatin have been shown to mitigate
dystrophy symptoms in mice (reviewed in [106]), down-
regulation of negative regulators of muscle differentiation like
myostatin can have the same effect (reviewed in [109]).
Myostatin is a secreted factor with sequence similarity to the
transforming growth factor-beta subfamily of proteins.
Mutations in myostatin in mice and cattle cause these
animals to have increased muscle mass [110,111], although
this can also be associated with negative health effects such
as increased mortality [112]. Down-regulation of myostatin in
the mdx mouse can help mitigate the symptoms of muscular
dystrophy [91,92] suggesting that decreased expression of
myostatin might be a viable therapy to treat people with
muscle disease, especially those in which muscle degenera-
tion is a secondary effect. Zebrafish also express myostatin
and may have two different forms of the gene [113,114].
Using zebrafish models, it should be possible to down-
regulate one or both forms of the gene in an attempt to rescue
phenotype in sapje or one of the other dystrophic mutants.
By performing these experiments in an animal model, it is
possible to assay effects (positive or negative) of gene
expression in all tissues.
5.4. Evaluating cell therapy in zebrafish models
Muscle is a normally regenerating tissue with satellite cells
providing an immediate precursor cell population. Upon
activation, satellite cells are able to divide and expand both in
vitro and in vivo, giving rise to later stage precursors and new
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the dystrophin gene, a cell-based approach was proposed for
delivery of normal dystrophin to diseased muscle [116,117].
Culture-expanded myogenic cells derived from normal muscle
were shown to fuse into mdxmouse muscle and produce normal
dystrophin [116,118]. These initially promising mouse studies
led to human trials in Duchenne Muscular Dystrophy patients
(reviewed in [119]). Unlike the mouse studies though, the
human experiments showed little, if any, donor-derived
dystrophin expression. This led in the late 1990s to a rethinking
of how the cells should be isolated, expanded and delivered to
correct the symptoms of disease.
It has become clear that there exist cells within muscle
likely to be more primitive than satellite cells [98,120–122].
These putative muscle stem cells have been purified from
mouse skeletal muscle using different methods and techni-
ques, including pre-plating [117,122,123], cell sorting
[55,98,120,124,125] and fractionation based on specific anti-
gens [126]. Although progenitor cells can be enriched using the
above purifications, selected cell populations are still hetero-
geneous suggesting that additional purifications could help
further enrich for cells with muscle engraftment capability.
Zebrafish are well suited for testing cell transplantation
potentials at any developmental stage. Early in development,
the animals are optically clear, allowing for tracking the fate of
transplanted fluorescently labeled cells [127]. Later in devel-
opment, as the fish become more pigmented, they become less
transparent and develop a fully functional immune system. In
this case, pigment mutants which retain their optical clarity
throughout development can be used to facilitate in vivo
tracking of fluorescently labeled transplanted cells at all
development stages. In addition, the immune system can be
suppressed through temporary exposure to irradiation. If
necessary, Traver et al. has also shown that the immune system
can be reconstituted in lethally irradiated zebrafish by
transplanting hematopoietic cells [128], almost exactly as in
mice.
Procedures for cell transplantation at all stages of zebrafish
development are well-established (reviewed in [129]). Since
zebrafish can be grown and irradiated in large numbers, it is
possible to prepare large numbers of animals for analysis very
quickly. In addition, since zebrafish are smaller than mice, it is
possible to transplant smaller quantities of cells for analysis.
While any labeled cell can be used, transgenic zebrafish
expressing GFP under different promoters have been created
[130]. Zebrafish muscle cells can be fractionated and injected
into hosts to assay their ability to engraft into muscle. Using this
assay, cells can be sequentially fractionated using many sorting
methods such as rhodamine 123 staining, alcohol dehydrogen-
ase fractionation, forward and side scatter FACS analysis and
preplating before assaying for muscle engraftment potential.
Purified muscle progenitor cells can then be characterized by
available microarray probe sets to identify cell-specific markers
that can then be used to isolate similar cell populations from
mammals.
To assay muscle engraftment potential in zebrafish, cells can
be efficiently transplanted directly into dechorinated blastulae(500 cell stage), injected directly into the circulation of a 48 h
post-fertilization (hpf) embryo, or injected into the muscle of an
adult zebrafish (reviewed in [129]). In each case, 100
transplantations can be easily performed in an afternoon. After
transplantation, the fate of the injected GFP+ cells can be
assayed by anesthetizing the hosts andmonitoring cell fate under
a fluorescent dissecting scope. After analysis, the fish can be
revived and reanalyzed at a later date. In our experience, muscle
engraftment can be assayed as early as 3–4 days after
transplantation, although 2 weeks is more optimal (Kunkel
laboratory, unpublished data). These advantages make the
zebrafish an ideal model to screen cell populations for muscle
engraftment potential.
6. Conclusion
Muscular dystrophies are a group of genetic diseases that
vary significantly in age of onset, severity of the disease, rate of
progression, modes of inheritance, and pattern of affected
muscle. More than 25 human genes have been identified that
when mutated, lead to various dystrophies; however, the
underlying pathways that result in shared dystrophic muscle
pathology are not completely understood. Studies suggest that
the small vertebrate zebrafish Danio rerio have muscle
structure and development similar to that of mammals, and
that the majority of muscle-related genes tested are present in
zebrafish. Genetic screens in zebrafish have already provided a
model for the most common human dystrophy, DMD. We
propose that additional dystrophic mutants will provide models
for other dystrophies, or may uncover additional dystrophy-
associated genes that will further our understanding of the
pathology of muscular dystrophy. In addition, the use of
zebrafish will allow us to analyze several different therapeutic
methods on a time scale not possible in mammals. The ability
to easily transplant labeled cells into zebrafish and analyze the
results will enable rapid screening of many cell populations to
help identify cells with the greatest engraftment potential for
cell-based therapy. While the activity of analogous cell
populations will have to be verified in mice, the screening
capabilities of zebrafish make the fish an attractive model. The
ability to quickly generate large numbers of tiny dystrophic
zebrafish also makes this animal ideal for screening chemical
libraries to identify new pharmacological agents for the
treatment of dystrophy. While the fish will never completely
replace other animal models of muscular dystrophy, the many
advantages of the zebrafish model make it an effective
complement to established mammalian systems helping to
provide further insight into specific questions related to
muscular dystrophy.
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